Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Design:
This will be a pilot trial evaluating the safety and immunogenicity of the WT-1 peptide vaccine in patients with hematologic malignancies. Ten patients with acute myelogenous leukemia (AML) or advanced myelodysplastic syndrome (MDS), will be enrolled. Patients will be vaccinated with a preparation of WT-1-derived native and synthetic peptides plus immunologic adjuvant Montanide ISA 51 VG (Seppic Pharmaceuticals, Fairfield, NJ) and Sargramostim (GM-CSF). One dose level will be tested.
Patients will receive 6 injections of the WT-1 vaccine. Doses will be given every 2 weeks. Each vaccine is given at a different location under the skin in the arm or leg. Patients will be monitored for 30 minutes after vaccination.
WT-1 vaccine is given with another substance, Montanide, which clumps the WT-1 vaccine and improves the immune response. Patients will also receive an injection of Sargramostim (GM-CSF) 2 days before each vaccination and again on the day of the WT-1 injection at the same spot. Sargramostim (GM-CSF) stimulates the body's white blood cells to boost the immune response. Patients may be taught to do the Sargramostim (GM-CSF) injection themselves in which case patients will be given a log sheet to record the injection time and location. If not, they will need to come for an additional 24 study visits.
To monitor their health while receiving the vaccine, patients will need the following tests and procedures as a part of regular cancer care.
- History and physical examination every 2 weeks
- Complete blood count (CBC) and comprehensive panel every 2 weeks
- Bone marrow aspirate at week 14 for patients with acute myelogenous leukemia or myelodysplastic syndrome.
Patients will need these tests and procedures to see whether the vaccine is causing an immune response:
- A skin test will be performed before patients start the study and again in the 8th and 14th weeks in which a small amount of the vaccine will be placed under the skin. Two days later, the site will be checked to see whether a bump or swelling has formed. Another substance which typically does cause a mild reaction (mumps) will also be placed under the skin to measure whether they have a normal immune reaction.
- We will take about 7 tablespoons of blood to measure their immune response. About 1 tablespoon of blood will be taken to measure the levels of WT-1 in their blood. Blood samples will be taken prior to receiving the first vaccination and prior to receiving the vaccination at weeks 6 and 12.
If the vaccine causes the patient to have an immune response, and their cancer does not grow, they may continue to receive the WT-1 vaccinations monthly for 6 more months. If this occurs, the patient will have a computed tomography (CT) scan or bone marrow test and immunology blood tests 2 weeks after the 9th and 12th vaccinations.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- H. Lee Moffitt Cancer Center and Research Institute
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Cytologic or histologic diagnosis of acute myelogenous leukemia or myelodysplastic syndrome confirmed at Moffitt Cancer Center.
- Patients with acute myelogenous leukemia will have completed induction chemotherapy, achieved first complete remission (CR) 1 or 2, and will have completed any planned postremission therapy (at discretion of treating physician),with no plan for allogenic or autologous transplant.
- Patients with myelodysplastic syndrome who according to the International Prognostic Scoring System (IPSS) are category Int-2 or greater, with disease that relapsed, progressed, or not responded to at least 1 prior course of approved therapy for MDS (i.e. hypomethylating agent or lenalidomide).
- Patients with AML/MDS must have documented WT-1 + disease. For purposes of this study, this may be either the demonstration of WT-1 protein on a pretreatment bone marrow biopsy or detectable disease with RQ-PCR. For patients in whom a bone marrow aspirate is not available or possible (e.g. "dry tap"), a peripheral blood sample may be used for WT-1 screening. In such cases, 10 cc of peripheral blood will be collected in a heparinized tube.
- At least 4 weeks must have elapsed between the patient's last chemotherapy or radiation treatment and the first vaccination.
- Karnofsky performance status ≥ 70%
Hematologic parameters:
- Absolute neutrophil count ≥ 1000/mcL (except for MDS, for which the parameter is ≥ 500/mcL)
- Platelets > 50 K/mcL (except for MDS for which the parameter is > 25 K/mcL and not transfusion dependent)
Biochemical parameters:
- Total bilirubin ≤ 2.0 mg/dl
- Aspartic transaminase (AST) and Alanine transaminase (ALT) ≤ 2.5 x upper limits of normal
- Creatinine ≤ 2.0 mg/dl
Exclusion Criteria:
- Pregnant or lactating women
- Patients with leptomeningeal disease
- Patients with active infection requiring systemic antibiotics, antiviral, or antifungal treatments
- Patients with serious unstable medical illness
- Patients taking systemic corticosteroids
- Patients with central nervous system (CNS) involvement with cancer/leukemia
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: WT-1 Analog Peptide Vaccine
Participants received 6 bi-weekly vaccinations over 10 weeks.
WT-1 vaccine was given with Montanide.
Participants also received an injection of Sargramostim (GM-CSF) two days before each vaccination and again on the day of the WT-1 injection at the same spot.
|
Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease.
Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month.
In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination.
In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
Outros nomes:
The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants With Adverse Events (AEs)
Prazo: 12 weeks to 6 months
|
Toxicities were tabulated according to the NCI Common Toxicity (version 3.0) by grade and category.
If more than one patient developed ≥ grade 3 non-hematologic toxicity or grade 4 hematologic toxicity, the study accrual was to be suspended immediately for a careful toxicity data evaluation.
Depending upon the findings of such safety/toxicity data assessment and consultation with the supporting pharmaceutical company, the principal investigator of this trial would have the option of terminating this trial permanently, amending the study protocol, or resuming the patient accrual.
|
12 weeks to 6 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Participants Whose Samples Demonstrated Immunological Response After Vaccination
Prazo: 12 weeks
|
Immune Response: Immune reactivity was measured for all participants. Immune response was measured by T cell proliferative response and DTH against WT-1 peptides. In patients with adequate samples, T cell gamma interferon release as measured by ELISPOT and/or multiparameter intracellular staining by flow cytometry were performed as well. ELISPOT Assay: CD4+ immune response, CD4+ and CD8+ response. The samples of participants' blood obtained at baseline and week 12 were tested for CD4 T cell proliferation, CD4 and CD8 T cell interferon release. Tetramer Analysis of WT1-specific Immune responses: subtle WT1 T cell expansion, positive by ELISPOT and T cell expansion. Delayed-type Hypersensitivity (DTH): measurable DTH response without overlap with ELISPOT or tetramer responders). Overall: any form of immune response. |
12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- MCC-15025
- INNO-305 WT-1 (Outro identificador: Innovive)
- 105946 (Outro identificador: USF IRB)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em WT-1
-
Ann & Robert H Lurie Children's Hospital of ChicagoConcluído
-
The Republican Research and Practical Center for...Belarusian State Medical UniversityConcluídoNeoplasias Pancreáticas | Células dendríticasBielorrússia
-
Changhua Christian HospitalRecrutamentoAtaxia Espinocerebelar | Fator de crescimento semelhante à insulina I | Medicina Tradicional ChinesaTaiwan
-
BioNTech SEPfizerConcluídoCOVID-19 | Infecção por SARS-CoV-2Estados Unidos
-
VA Office of Research and DevelopmentConcluídoTranstorno de Estresse Pós-TraumáticoEstados Unidos
-
Sellas Life Sciences GroupUnited States Department of DefenseConcluídoMesotelioma Pleural MalignoEstados Unidos
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Innovive PharmaceuticalsConcluídoSíndromes Mielodisplásicas | Leucemia | Câncer de pulmão | Mesotelioma maligno | Câncer Primário de Cavidade PeritonealEstados Unidos
-
University of PennsylvaniaAdaptimmuneConcluídoCélulas T autólogas específicas para gag de alta afinidade redirecionadas para terapia gênica de HIVInfecções por HIVEstados Unidos
-
Yağmur Saraç GülRecep Tayyip Erdogan University Scientific Research Projects CoordinatorConcluídoInflamação | Estresse oxidativo | Gengivite; CrônicaPeru
-
Maria LiljeforsKarolinska Institutet; Swedish Institute for Infectious Disease Control; Cyto...Concluído